Cardiac Neuromodulation for Heart Failure

Status Recruiting

Clinical Trial Summary

This investigation will evaluate the ability of the Moderato® System to safely and effectively deliver CNT, to reduce sympathetic activity in heart failure patients

Clinical Trial Description

This will be a single center, non-randomized observational study. The Moderato® System is approved for marketing in Europe (has a CE mark) for the treatment of high blood pressure in patients requiring standard cardiac pacing. The therapy delivered by the Moderato® System is referred to as CNT (Cardiac Neuromodulation Therapy). Heart failure patients is a population for which the Moderato® device is currently not indicated. Subjects requiring an implantable cardiac defibrillator (ICD) implantation or replacement and meeting study inclusion and exclusion criteria will be eligible to participate in the study. The study procedure will take place during the ICD implantation (or replacement). The whole procedure will be performed according to standard of care for ICD implantations (or replacements) including periprocedural prophylactic antibiotics prophylactic. To reduce the time of wound exposure, the setup of system for invasive measurements will be done before the ICD implant (or replacement) procedure begins. The groin area will be prepared and draped. After applying local anesthesia, a 7Fr sheath will be inserted into the femoral artery. A small dose of heparin (~5000 units) will be administered intravenously to prevent formation of blood clots. Under fluoroscopic guidance, a standard conductance catheter (CD Leycom CA-71103-PL, CE marked) will be advanced into the left ventricle. The arterial line will be used to measure arterial pressure. This completes the measuring system setup. Then, ICD right atrial lead and right ventricular lead will be implanted in standard positions according to standard institutional practices. The leads will be connected to a BackBeat Moderato® System IPG, externally to the patient using a single use, sterile Pacing System Analyzer (PSA) cable provided by the hospital. The Moderato® IPG, approved for chronic CNT delivery in hypertensive patients, will function in this trial as a temporary external CNT signal generator for acute application of the therapy. A range of CNT signal parameters will be used to assess the effect on sympathetic activity. Ventricular pressure and volume readings from the conductance catheter and arterial pressure readings will be recorded and analyzed to assess the effect of CNT signals on cardiac function, sympathetic activity and blood pressure. The effects of CNT signal over a range of parameter settings will be studied over a period of time no longer than one hour. In this study, none of the Moderato® system components will be in contact with the patient. The Moderato® IPG will be used solely as an external CNT signal generator and deliver signals to the patient through the PSA cable and the ICD leads. When CNT signal activation is complete, data recording will be stopped, the conductance catheter will be removed, the cable connecting the IPG to the leads disconnected, and ICD implantation will proceed normally. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04573699
Study type	Observational
Source	BackBeat Medical Inc
Contact	Yuval Mika, Ph.D.
Phone	+1(856)912-3155
Email	ymika@orchestrabiomed.com
Status	Recruiting
Phase
Start date	December 15, 2020
Completion date	May 30, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04452149` - Algorithm Using LINQ Sensors for Evaluation And Treatment of Heart Failure	N/A
Withdrawn	`NCT03005184` - Mechanism(s) Underlying Cardiovascular Effects of ARB/NEP Inhibition - Aim 2	Phase 2
Not yet recruiting	`NCT01669395` - Severe Heart Failure and Homebased Rehabilitation - An Intersectoral Randomized Controlled Trial	N/A
Recruiting	`NCT05835063` - A Study to Improve Physician-Youth Communication and Medical Decision Making	N/A
Completed	`NCT03895073` - HEart fAiluRe evaluaTion Questionnaire
Completed	`NCT03095196` - Multipolar CRT-d and Diabetes	N/A
Recruiting	`NCT03180320` - Baduanjin-eight-silken-movement With Self-efficacy Building for Patients With Chronic Heart Failure (BESMILE-HF Study)	N/A
Completed	`NCT06233695` - Gender-based Differences in the Outcome of Treatment With Aldosterone Antagonists in Patients With Heart Failure
Withdrawn	`NCT03947853` - Clinical Study to Evaluate the Predictive Value of the Heart Failure Questionnaire (HF-Q) for the Occurrence of Μajor Αdverse Cardiovascular Events (MACE) in Patients With Symptomatic Heart Failure
Recruiting	`NCT05934487` - PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III	N/A
Recruiting	`NCT04829617` - Promoting Well-being and Health in Heart Failure	N/A
Recruiting	`NCT03538990` - Effect of DASH Eating Pattern on Heart Failure Outcomes	N/A
Recruiting	`NCT05487365` - Implementation and Cost-evaluation of a Smartphone-based Telemonitoring and Digital Support in Patients With HF	N/A
Not yet recruiting	`NCT06270875` - Addressing Pain Through Navigator-Led Palliative Care Optimized for Heart Failure (ADAPT-HF)	N/A
Completed	`NCT03592836` - Diuretic Response in Advanced Heart Failure: Bolus Intermittent vs Continuous INfusion	Phase 3
Not yet recruiting	`NCT06097481` - Narrative Intervention for Chronic Illness- Heart Failure Trial (NICI-HF)	Phase 1/Phase 2
Completed	`NCT01560871` - Effects of a Walking Program and Inspiratory Muscle Training in Individuals With Chronic Heart Failure	N/A
Completed	`NCT03387813` - Hemodynamic-GUIDEd Management of Heart Failure	N/A
Enrolling by invitation	`NCT05885607` - Early Metabolic Adaptations to SGLT2 Inhibition in Heart Failure
Active, not recruiting	`NCT04012944` - SIRONA 2 Trial Heart Failure NYHA Class III	N/A